Scribe Therapeutics
Rewriting medicine with molecular engineering
- Headquarters
- Alameda, California
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- scribetx.com
- Total Funding
- $100.0M
- Last Round
- $100.0M Series BMar 2021
- Rounds
- 1
About
Scribe Therapeutics is a molecular engineering company developing best-in-class CRISPR-based genetic medicines, founded by Nobel Prize-winning CRISPR pioneer Jennifer Doudna and colleagues at UC Berkeley. The company engineers optimized in vivo CRISPR systems targeting cardiometabolic diseases, with partnerships with Eli Lilly and Sanofi and programs projected to enter the clinic in mid-2026.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Mar 2021
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Healthcare company in Europe
Mehiläinen is a leading Finnish private healthcare company providing medical, health, and special...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Biopharmaceutical services company